263 related articles for article (PubMed ID: 29021399)
1. Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?
Cromer D; Pinkevych M; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021399
[TBL] [Abstract][Full Text] [Related]
2. HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.
Pinkevych M; Cromer D; Tolstrup M; Grimm AJ; Cooper DA; Lewin SR; Søgaard OS; Rasmussen TA; Kent SJ; Kelleher AD; Davenport MP
PLoS Pathog; 2015 Jul; 11(7):e1005000. PubMed ID: 26133551
[TBL] [Abstract][Full Text] [Related]
3. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 May; 91(9):. PubMed ID: 28202759
[TBL] [Abstract][Full Text] [Related]
4. Modeling the timing of antilatency drug administration during HIV treatment.
Petravic J; Martyushev A; Reece JC; Kent SJ; Davenport MP
J Virol; 2014 Dec; 88(24):14050-6. PubMed ID: 25253352
[TBL] [Abstract][Full Text] [Related]
5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
6. Therapeutics for HIV-1 reactivation from latency.
Sgarbanti M; Battistini A
Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
[TBL] [Abstract][Full Text] [Related]
7. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.
López-Huertas MR; Gutiérrez C; Madrid-Elena N; Hernández-Novoa B; Olalla-Sierra J; Plana M; Delgado R; Rubio R; Muñoz-Fernández MÁ; Moreno S
Sci Rep; 2020 Dec; 10(1):22286. PubMed ID: 33339855
[TBL] [Abstract][Full Text] [Related]
8. Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers.
Conway JM; Perelson AS; Li JZ
PLoS Comput Biol; 2019 Jul; 15(7):e1007229. PubMed ID: 31339888
[TBL] [Abstract][Full Text] [Related]
9. Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.
Pinkevych M; Fennessey CM; Cromer D; Tolstrup M; Søgaard OS; Rasmussen TA; Keele BF; Davenport MP
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118123
[TBL] [Abstract][Full Text] [Related]
10. Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.
Hill AL; Rosenbloom DI; Goldstein E; Hanhauser E; Kuritzkes DR; Siliciano RF; Henrich TJ
PLoS Pathog; 2016 Apr; 12(4):e1005535. PubMed ID: 27119536
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.
Noel N; Peña R; David A; Avettand-Fenoel V; Erkizia I; Jimenez E; Lecuroux C; Rouzioux C; Boufassa F; Pancino G; Venet A; Van Lint C; Martinez-Picado J; Lambotte O; Sáez-Cirión A; Prado JG
J Virol; 2016 Jul; 90(13):6148-6158. PubMed ID: 27122576
[TBL] [Abstract][Full Text] [Related]
12. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
13. Latency reversal and viral clearance to cure HIV-1.
Margolis DM; Garcia JV; Hazuda DJ; Haynes BF
Science; 2016 Jul; 353(6297):aaf6517. PubMed ID: 27463679
[TBL] [Abstract][Full Text] [Related]
14. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
Abgrall S; Duval X; Joly V; Descamps D; Matheron S; Costagliola D;
Clin Infect Dis; 2003 Dec; 37(11):1517-26. PubMed ID: 14614675
[TBL] [Abstract][Full Text] [Related]
16. What can we do to reduce the viral reservoir in HIV-1-infected individuals?
Pohlmeyer CW; Walker-Sperling VE; Blankson JN
Future Microbiol; 2016 Jul; 11():839-42. PubMed ID: 27416850
[No Abstract] [Full Text] [Related]
17. Stochastic Dynamics of the Latently Infected Cell Reservoir During HIV Infection.
Azoz SA; Coombs D
Bull Math Biol; 2019 Jan; 81(1):131-154. PubMed ID: 30298198
[TBL] [Abstract][Full Text] [Related]
18. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
19. Underlying mechanisms of HIV-1 latency.
Romani B; Allahbakhshi E
Virus Genes; 2017 Jun; 53(3):329-339. PubMed ID: 28258391
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Reservoirs During Suppressive Therapy.
Barton K; Winckelmann A; Palmer S
Trends Microbiol; 2016 May; 24(5):345-355. PubMed ID: 26875617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
